SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001140361-22-019495
Filing Date
2022-05-17
Accepted
2022-05-17 07:25:29
Documents
14
Period of Report
2022-05-13
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K brhc10037825_8k.htm   iXBRL 8-K 32704
2 EXHIBIT 4.1 brhc10037825_ex4-1.htm EX-4.1 29502
3 EXHIBIT 10.1 brhc10037825_ex10-1.htm EX-10.1 33598
  Complete submission text file 0001140361-22-019495.txt   247185

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA aqst-20220513.xsd EX-101.SCH 3926
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE aqst-20220513_lab.xml EX-101.LAB 23288
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE aqst-20220513_pre.xml EX-101.PRE 16552
8 EXTRACTED XBRL INSTANCE DOCUMENT brhc10037825_8k_htm.xml XML 4225
Mailing Address 30 TECHNOLOGY DRIVE WARREN NJ 07059
Business Address 30 TECHNOLOGY DRIVE WARREN NJ 07059 908-941-1900
Aquestive Therapeutics, Inc. (Filer) CIK: 0001398733 (see all company filings)

IRS No.: 208623253 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38599 | Film No.: 22932236
SIC: 2834 Pharmaceutical Preparations